The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
Testing personalized medicine: patient and physician expectations of next-generation genomic sequencing in late-stage cancer care
Open accessAbstract
Developments in genomics, including next-generation sequencing technologies, are expected to enable a more personalized approach to clinical care, with improved risk stratification and treatment selection. In oncology, personalized medicine is particularly advanced and increasingly used to identify oncogenic variants in tumor tissue that predict responsiveness to specific drugs. Yet, the translational research needed to validate these technologies will be conducted in patients with late-stage cancer and is expected to produce results of variable clinical significance and incidentally identify genetic risks. To explore the experiential context in which much of personalized cancer care will be developed and evaluated, we conducted a qualitative interview study alongside a pilot feasibility study of targeted DNA sequencing of metastatic tumor biopsies in adult patients with advanced solid malignancies. We recruited 29/73 patients and 14/17 physicians; transcripts from semi-structured interviews were analyzed for thematic patterns using an interpretive descriptive approach. Patient hopes of benefit from research participation were enhanced by the promise of novel and targeted treatment but challenged by non-findings or by limited access to relevant trials. Family obligations informed a willingness to receive genetic information, which was perceived as burdensome given disease stage or as inconsequential given faced challenges. Physicians were optimistic about long-term potential but conservative about immediate benefits and mindful of elevated patient expectations; consent and counseling processes were expected to mitigate challenges from incidental findings. These findings suggest the need for information and decision tools to support physicians in communicating realistic prospects of benefit, and for cautious approaches to the generation of incidental genetic information.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“These burdens are factors that determine whether patients have PM tests or treatments performed [61, 67].”
From Patients’ and professionals’ views related to ethical issues in precision medicine: a mixed research synthesis (2021) · cites this paper as [67]
Citations
Cites
(2006) · Cited by 18,730
Constructing Grounded Theory. A Practical Guide Through Qualitative Analysis
Boyle, C., & Barker, A. (2006) · QMiP Bulletin · doi:10.53841/bpsqmip.2006.1.2.36 · Cited by 11,845
The SAGE handbook of qualitative research
(2005) · Choice Reviews Online · doi:10.5860/choice.43-1330 · Cited by 10,173
What's in a name? Qualitative description revisited
Sandelowski, M. (2010) · Research in Nursing & Health · doi:10.1002/nur.20362 · Cited by 4,975
ACMG recommendations for reporting of incidental findings in clinical exome and genome sequencing
Green, R. C., Berg, J. S., Grody, W. W., Kalia, S. S., Korf, B. R., Martin, C. L., McGuire, A. L., Nussbaum, R. L., O’Daniel, J. M., Ormond, K. E., et al. (2013) · Genetics in Medicine · doi:10.1038/gim.2013.73 · Cited by 2,544
The Sage Handbook of Qualitative Research
(2009) · Qualitative Market Research An International Journal · doi:10.1108/13522750910948815 · Cited by 2,359
The Path to Personalized Medicine
Hamburg, M. A., & Collins, F. S. (2010) · New England Journal of Medicine · doi:10.1056/nejmp1006304 · Cited by 1,970
BRCA1 Testing in Families With Hereditary Breast-Ovarian Cancer
Lerman, C. E. (1996) · JAMA · doi:10.1001/jama.1996.03530480027036 · Cited by 826
Personalized Oncology Through Integrative High-Throughput Sequencing: A Pilot Study
Roychowdhury, S., Iyer, M. K., Robinson, D. R., Lonigro, R. J., Wu, Y.-M., Cao, X., Sundaram, S. K., Sam, L. T., Balbin, O. A., Quist, M. J., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3003161 · Cited by 638
Personalized Medicine: Progress and Promise
Chan, I. S., & Ginsburg, G. S. (2011) · Annual Review of Genomics and Human Genetics · doi:10.1146/annurev-genom-082410-101446 · Cited by 409
Cited by
Sorted by citations
Stockley, T. L., Oza, A. M., Berman, H. K., Leighl, N. B., Knox, J. J., Shepherd, F. A., Chen, E. X., Krzyzanowska, M. K., Dhani, N. C., Joshua, A. M., et al. (2016) · Genome Medicine · doi:10.1186/s13073-016-0364-2 · Cited by 276
Self-citationTranslating cancer genomes and transcriptomes for precision oncology
Roychowdhury, S., & Chinnaiyan, A. M. (2015) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21329 · Cited by 168
Mackley, M. P., Fletcher, B., Parker, M. J., Watkins, H. C., & Ormondroyd, E. (2016) · Genetics in Medicine · doi:10.1038/gim.2016.109 · Cited by 162
Freedman, A. N., Klabunde, C. N., Wiant, K. F., Enewold, L., Gray, S. W., Filipski, K. K., Keating, N. L., Leonard, D. G. B., Lively, T., McNeel, T. S., et al. (2018) · JCO Precision Oncology · doi:10.1200/po.18.00169 · Cited by 153
Genomic testing in cancer: Patient knowledge, attitudes, and expectations
Blanchette, P., Spreafico, A., Miller, F. A., Chan, K., Bytautas, J., Kang, S., Bedard, P. L., Eisen, A. F., Potanina, L., Holland, J., et al. (2014) · Cancer · doi:10.1002/cncr.28807 · Cited by 90
Self-citation
Metadata
- Authors
- Miller, F. A., Hayeems, R. Z., Bytautas, J. P., Bedard, P. L., Ernst, S., Hirte, H., Hotte, S., Oza, A., Razak, A., Welch, S., Winquist, E., Dancey, J., & Siu, L. L.
- Affiliations
- University of Toronto (CA)
- University Health Network (CA)
- London Health Sciences Centre (CA)
- Juravinski Cancer Centre (CA)
- Ontario Institute for Cancer Research (CA)
- Corresponding author
- Miller, Fiona A
- ORCID
- Venue
- European Journal of Human Genetics
- Published
- 2013-07-17
- Volume
- 22
- Issue
- 3
- Pages
- 391-395
- ISSN
- 1018-4813 (ISSN-L)
- 1476-5438
- PMC
- PMC3925281
- OpenAlex
- W2025342001
- Cited by
- 116
- References
- 50
- Citations by year
- 2026: 5 · 2025: 2 · 2024: 4 · 2023: 11 · 2022: 7 · 2021: 11 · 2020: 15 · 2019: 13 · 2018: 9 · 2017: 8 · 2016: 14 · 2015: 10 · 2014: 7
- FWCI
- 6.86
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- European Journal of Human Genetics (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Ontario Institute for Cancer Research
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › BRCA gene mutations in cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Ethics in Clinical Research
- Keywords
- personalized medicine, next-generation sequencing, late-stage cancer, metastatic solid tumors, patient expectations, physician expectations, targeted sequencing, incidental finding, genetic counseling, informed consent, family responsibilities, research participation, physician-patient communication, translational research
- MeSH terms
- Adult, Aged, Aged, 80 and over, Decision Making, DNA, Neoplasm, Female, Humans, Male, Middle Aged, Neoplasm Staging, Neoplasms, Patient Education as Topic, Patients, Physicians, Genome, Human, Sequence Analysis, DNA, Genetic Predisposition to Disease, Precision Medicine, Self Report, High-Throughput Nucleotide Sequencing
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review